NEW YORK, March 13, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com navigates the Biotechnology space with focus on Nektar Therapeutics (NASDAQ: NKTR), Seattle Genetics Inc. (NASDAQ: SGEN), Dynavax Technologies Corp. (NASDAQ: DVAX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). According to a Barron's report, the iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF's 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector. Download the free research reports on these stocks today:
California headquartered Nektar Therapeutics' stock climbed 0.13%, finishing last Friday's trading session at $15.34. A total volume of 1.09 million shares was traded. The Company's shares have surged 16.74% in the last month, 24.41% over the previous three months, and 25.02% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 17.08% and 3.43%, respectively. Additionally, shares of Nektar Therapeutics, which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the US, have a Relative Strength Index (RSI) of 65.66.
On March 01st, 2017, Nektar Therapeutics announced revenue of $37.5 million for Q4 2016 compared to $39.4 million in Q4 2015. The Company's revenue for the year ended December 31st, 2016, was $165.4 million compared to $230.8 million in full year 2015. Nektar Therapeutics' net loss for Q4 2016 was $42.2 million, or $0.28 loss per share, compared to a net loss of $54.1 million, or $0.40 loss per share, in Q4 2015. See our free and comprehensive research report on NKTR at:
Shares in Washington headquartered Seattle Genetics Inc. ended at $67.96, rising 1.28% from the last trading session. The stock recorded a trading volume of 621,241 shares. The Company's shares have advanced 10.49% in the past month, 4.41% in the previous three months, and 28.79% on an YTD basis. The stock is trading 11.83% and 26.66% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Seattle Genetics, which develops and commercializes targeted therapies to treat cancer worldwide, have an RSI of 61.23.
On March 06th, 2017, Seattle Genetics announced that the US Food and Drug Administration (FDA) has lifted the clinical hold announced on December 27, 2016, on phase-1 trials of vadastuximab talirine (SGN-CD33A; 33A) in acute myeloid leukemia (AML). Seattle Genetics will resume two phase-1 trials of vadastuximab talirine. The first is combination treatment with standard of care, or 7+3, chemotherapy in newly diagnosed younger AML patients and the second is monotherapy and combination treatment with hypomethylating agents in both newly diagnosed and relapsed AML patients. SGEN free research report PDF is just a click away at:
On Friday, shares in California headquartered Dynavax Technologies Corp. recorded a trading volume of 689,560 shares. The stock closed the day flat at $5.90. The Company's shares have gained 47.50% in the last one month, 18.00% over the previous three months, and 49.37% on an YTD basis. The stock is trading 34.29% above its 50-day moving average. Additionally, shares of Dynavax Technologies, which discovers and develops novel vaccines and therapeutics in the US, have an RSI of 66.77.
On February 28th, 2017, Dynavax announced that the US FDA has accepted for review Dynavax's responses to the Complete Response Letter issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the Company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older. Sign up for your complimentary report on DVAX at:
At the close of trading on Friday, shares in California headquartered BioMarin Pharmaceutical Inc. recorded a trading volume of 870,538 shares. The stock finished the session 1.73% higher at $92.53. The Company's shares have gained 1.79% in the past month, 14.21% in the previous three months, and 11.70% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.74% and 4.03%, respectively. Furthermore, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 54.84.
On February 23rd, 2017, BioMarin Pharmaceutical announced that for Q4 2016, GAAP net loss was $91 million, or ($0.53) per basic and diluted share, compared to GAAP net income of $69 million, or $0.43 and $0.39 per basic and diluted share, respectively, for Q4 2015. For Q4 2016, total BioMarin Pharma's revenues were $300 million, up 32% on a y-o-y basis.
On March 02nd, 2017, research firm Instinet initiated a 'Neutral' rating on the Company's stock, with a target price of $93 per share. Register for free on Stock-Callers.com and download the latest research report on BMRN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA